Sirisha Mushti

Sirisha Mushti

National Center for Toxicological Research - Jefferson / United States
Medical and Health Sciences / Biostatistics
AD Scientific Index ID: 4403433
-
person_outline Sirisha Mushti's MOST POPULAR ARTICLES
1-) FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapyD Kazandjian, DL Suzman, G Blumenthal, S Mushti, K He, M Libeg, ...The oncologist 21 (5), 634-642, 20163952016
2-) US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumabM Hazarika, MK Chuk, MR Theoret, S Mushti, K He, SL Weis, AH Putman, ...Clinical Cancer Research 23 (14), 3484-3488, 20171232017
3-) A novel model of human implantation: 3D endometrium-like culture system to study attachment of human trophoblast (Jar) cell spheroidsH Wang, F Pilla, S Anderson, S Martínez-Escribano, I Herrer, ...Molecular human reproduction 18 (1), 33-43, 20121412012
4-) Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trialsSL Mushti, F Mulkey, R SridharaClinical Cancer Research 24 (10), 2268-2275, 20181392018
5-) Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisJA Beaver, M Hazarika, F Mulkey, S Mushti, H Chen, K He, R Sridhara, ...The Lancet Oncology 19 (2), 229-239, 20181382018